Sponsoring Agency HHS
    POP 7/1/16 - 6/30/21 (4 years)


The Development Therapeutics Program (DTP) of the National Cancer Institute (NCI) Division of Cancer Treatment and Diagnosis (DCTD) is soliciting preclinical toxicology of drugs developed for cancer patients. Investigations that profile and characterize the toxicological risk of these compounds to healthy organs are essential to the preclinical development phase for potential new drugs. Data generated from these studies are evaluated in light of potential human toxicity risk and additionally, form a major portion of the information required by the Food and Drug Administration for an Investigational New Drug Application (IND). Such laboratory investigations comprise the primary responsibility of this concept and of the Toxicology & Pharmacology Branch (TPB) within the DTP.

  • $1.6m Aggregate Dollars Obligated
  • $1.6m Aggregate Base & Exercised Options
  • $1.6m Aggregate Base & All Options (Ceiling)

Market Stats Related Contracts